Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.4352W HIGH $10.47
Volume
20.64 K
Value Traded
11.70 K
Short % Float
-
Days to Cover
2.1
+12.96%Week
-17.15%1 Month
-27.78%3 Month
-50.58%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
34.26 M
EPS (TTM)
0.09
P/E Ratio
43.45
Ent. Value
34.25 M
Total Shares
8.54 M
Float Shares
-
Insiders
7.36%
Institutions
0.28%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
IBO Catalyst Timeline
Dated clinical, regulatory and corporate events for Impact BioMedical, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Impact BioMedical, Inc.
10Total events
4Upcoming
3Tier-1 (high impact)
2025 to 2026Coverage
Upcoming catalysts 2
TBD
T1Acquisition
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 5
●Corporate ApprovalCorporate
Zoar Limited files Form F-4 registration statement with SEC for business combination with Impact BioMedical
●Corporate ApprovalCorporate
Stockholders approved second reverse stock split (1-for-12.48 to 1-for-50)
Past FDA Catalysts and PDUFA Decisions
How IBO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every IBO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DSS, INC.10% Owner | Sell | -156 589,518 held | $7.06 | 09/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IBO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in IBO for Q2 2026. | ||||
Ownership Trends
IBO Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
26.3K
Shares Sold Short
-12.9% vs prior count
2.1 Moderate
Days to Cover
trading days of normal volume to buy every short share back
12.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IBO ranks across every disease it competes in
Competitive Position is a premium feature
See how IBO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIBO News
-IBO
Nov 3, 2026▲ +5.5%today
Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination
Impact Biomedical Inc. and Zoar Limited announced that the SEC declared effective the Form F-4 registration statement for their business combination. A special meeting for stockholders is set for November 13, 2026, to vote on the merger. The combined entity will operate as Zoar Limited, focusing on pharmaceutical development.
Read more →-IBO
Sep 16, 2026▼ -5.9%on this news
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)
Impact Biomedical Inc. has filed a Form F-4 registration statement with the SEC regarding its proposed merger with Zoar Ltd. This filing is seen as a crucial step towards completing the business combination, which aims to establish a pharmaceutical company focused on active pharmaceutical ingredients. The merger requires approval from Impact's stockholders and the SEC.
Read more →-IBO
Sep 15, 2026▲ +9.3%on this news· ran to +22% by day 3shared move
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
Impact Biomedical Inc. announced a 1 for 12.62 reverse stock split to facilitate its merger with Zoar Limited. The corrected exchange ratio allows stockholders to receive one share of Zoar for each share of Impact held. The reverse split will take effect on September 23, 2026, and aims to support the company's continued listing on the NYSE American Exchange.
Read more →-IBO
Sep 11, 2026▲ +5.2%on this news· ran to +24% by day 3shared move
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)
Impact BioMedical Inc. announced a 1 for 12.62 reverse stock split effective September 23, 2026, to facilitate its merger with Zoar Ltd. This move aims to enhance the company's listing status and support the merger's completion. Stockholders will receive shares of Zoar Ltd. post-merger, but the reverse split does not assure compliance with NYSE standards.
Read more →-IBO
Apr 3, 2026▲ +8.4%on this news· ran to +20% by day 3
Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
Impact BioMedical Inc. reported a 'going concern' audit opinion in its 2025 10-K filing, indicating financial uncertainties. Despite this, the company is moving forward with plans to merge with Dr. Ashley's Ltd., expected to finalize by July 1, 2026. The announcement does not alter the financial statements for 2025.
Read more →-IBO
Jun 21, 2025▲ +344.6%on this news
Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger
Dr Ashleys Limited and Impact BioMedical Inc. have announced a strategic merger, aiming to enhance their combined market reach and accelerate the development of innovative pharmaceutical treatments. The transaction will involve Dr Ashleys acquiring Impact BioMedical through a reverse merger, resulting in a new entity traded on the NYSE American under the name 'Dr Ashleys Limited.' Both companies have received board approval for the merger, which will allow them to better capitalize on their respective strengths in research and development. The merger is subject to approval from Impact BioMedical's shareholders and regulatory authorities.
Read more →-IBO
Sep 16, 2024Impact BioMedical Inc. Announces Pricing of Initial Public Offering
Impact BioMedical Inc. has announced the pricing for its initial public offering (IPO), offering 1,500,000 shares at $3.00 per share. The shares are scheduled to start trading on the NYSE American under the ticker symbol 'IBO' on September 16, 2024. Additionally, the company has provided the underwriters a 45-day option to purchase 225,000 additional shares at the same price. The IPO is expected to close on September 17, 2024, pending customary closing conditions.
Read more →About Impact BioMedical, Inc.
Headquarters1400 BROADFIELD BLVD., HOUSTON, TX, 77084
BIOPHARMAWATCH ELITE PLUS
Trade the next IBO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime